GlassScriptPhysician profile
Biljana Markovic
NPI 1922460419
$2,576.73
in general payments reported to CMS, 2019-2025
21 companies · $1,339 in 2025
The $1,339 reported for 2025 was more than what 89% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $348 · 2023: $546 · 2024: $344 · 2025: $1,339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,229.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,228.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $388.65 | 2023-2025 | Eliquis, Camzyos |
| Astrazeneca Pharmaceuticals LP | $283.12 | 2023-2025 | Farxiga, Brilinta, Wainua |
| Boehringer Ingelheim Pharmaceuticals, INC. | $235.84 | 2022-2025 | Jardiance |
| Boston Scientific Corporation | $226.48 | 2023-2025 | Watchman Access System |
| Pfizer INC. | $213.96 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $189.08 | 2025 | |
| Amgen INC. | $160.84 | 2023-2025 | Repatha, Repatha |
| Philips North America LLC | $156.18 | 2025 | Igt Devices Undivided, Lm Undivided |
| Medtronic, INC. | $146.46 | 2022-2023 | Reveal Linq |
| Impulse Dynamics (USA) INC. | $134.81 | 2024 | Optimizer |
| Cardiovascular Systems INC. | $120.16 | 2022 | |
| Novartis Pharmaceuticals Corporation | $61.34 | 2024-2025 | |
| Novo Nordisk INC | $41.27 | 2025 | Wegovy |
| Regeneron Healthcare Solutions, INC. | $39.17 | 2025 | Evkeeza |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $38.70 | 2025 | Lifevest |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $32.55 | 2024-2025 | Verquvo |
| Procyrion, INC. | $30.71 | 2025 | Aortix System |
| Esperion Therapeutics, INC. | $21.43 | 2025 | Nexletol |
| Cvrx, INC. | $21.10 | 2024-2025 | Barostim Neo System |
| Scpharmaceuticals INC. | $17.88 | 2024 | |
| Kaleo, INC. | $17.00 | 2024 | Auvi-Q |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Biljana Markovic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.